iPS Cells

Sundin
Scientists in a lab celebrating conditional approval of iPS cell products for treating Parkinson's and heart disease.
Larawang ginawa ng AI

Health ministry panel conditionally approves iPS cell products

Iniulat ng AI Larawang ginawa ng AI

A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.

Gumagamit ng cookies ang website na ito

Gumagamit kami ng cookies para sa analytics upang mapabuti ang aming site. Basahin ang aming patakaran sa privacy para sa higit pang impormasyon.
Tanggihan